New reporting from The New York Times raises important questions about how clinical trials are conducted and overseen—and what that may mean for patient safety and informed consent.
Clinical trials are essential, but they do not always capture the full picture of how medications affect individuals in real-world settings. Early warning signs—especially medication-induced effects like akathisia—can be missed or misunderstood. In some previous clinical drug trials, akathisia was miscoded, downplaying the likely cause of suicidality and suicide as adverse drug effects and events.
At MISSD, we emphasize the importance of:
Careful monitoring after starting, stopping, or changing medications
Listening closely to patient-reported experiences
Recognizing early signs of medication-induced distress
These steps can help prevent serious and sometimes life-threatening outcomes.
A recent article spotlights important questions about antidepressant use in children. Analyses suggest limited benefit in certain cases, while prescribing rates continue to rise. Other findings highlight the need for careful monitoring and greater awareness of potential risks—especially with longer-term use.
These concerns underscore a broader issue: how we understand and respond to childhood distress. Children and families deserve a full range of support, including evidence-based therapies and non-drug approaches.
We appreciate this article’s intention to share information about antidepressants for older adults and its attention to common side effects such as weight changes, cardiovascular effects, and drug interactions.
However, one serious risk is not addressed: medication-induced akathisia.
We’re encouraged to see increased awareness of prescribed harm and the growing number of lived experiences being shared: https://prescribed-harm.com/
At MISSD, we have amplified similar stories to improve patient safety and deepen understanding of akathisia and related medication-induced harms.
While MISSD focuses on akathisia, it is not the only form of medication-induced harm that can precipitate suicide. Other serious effects may include post-SSRI sexual dysfunction (PSSD), emotional blunting, and loss of emotional responsiveness.
Adverse drug events are among the leading causes of death, yet remain widely under-recognized. Sharing lived experience helps improve recognition, informed consent, and ultimately—saves lives.
At MISSD, we regularly feature and amplify first-person accounts that illuminate the very real risks of adverse med effects—particularly the torment of akathisia and protracted withdrawal syndromes. Lori Daniels’ latest essay, ‘I Can Barely Breathe: The Journey Continues,’ is one such account. She was entangled in a system amid a circle of misdiagnosis—beginning with a coerced introduction to neuroleptics as a teenager and a cocktail of drugs that treated side effects with more side effects.
Her description of ongoing symptoms (akathisia, dystonia, myoclonic jerks, insomnia, and the sense that ‘breathing’ itself must be redefined) aligns with what countless others have reported when attempting to withdraw from long-term psychiatric drug use. Too often, these symptoms are dismissed or misattributed back to the original ‘disorder.’ We are grateful for voices like Lori’s and her full story that can help reduce these avoidable harms.
